Clinical significance of axillary findings in patients with lymphoma during follow-up with 18F-fluorodeoxyglucose-PET

Charoula S. Tsamita, Arber Golemi, Lapci Egesta, Paolo Castellucci, Cristina Nanni, Vittorio Stefoni, Gaia Grassetto, Domenico Rubello, Monica Tani, Pier Luigi Zinzani, Stefano Fanti

Research output: Contribution to journalArticle

Abstract

Purpose The aim of this study was to evaluate the clinical significance of positive axillary findings in patients with Hodgkin's disease and non-Hodgkin's lymphoma during follow-up with 18F-fluorodeoxyglucose-PET. Materials and methods We retrospectively reviewed PET scans carried out in 543 patients during follow-up. Patients with reports describing any increased fluorodeoxyglucose uptake at the axillary level were selected (106 cases) and final assessment of the findings was available in 78 patients (17 Hodgkin's disease, 51 non-Hodgkin's lymphoma). PET scans were performed after standard procedure and reports were interpreted as positive or negative on the basis of visual analysis. At the moment of the scan all patients had no clinical or laboratory sign of relapse, and had not received therapy for at least 6 months. All PET results were compared with other diagnostic procedures (ultrasonography and computed tomography), biopsy and/or follow-up data. Results Of 78 patients, 24 were PET positive in one axilla, 23 had axillary findings and one or more other extra axillary sites, five patients were positive in both axillas and 26 were positive in both axillas and one or more other sites. Of the 24 patients with single axillary finding, the result for five was true positive and for 19 it was false positive. Sixteen cases of the 23 patients with PET positive at one axilla and other sites had a true positive result, whereas seven had a false positive result. Only one of five patients with both axillas being positive at PET turned out to be true positive; finally, 23 cases from the 26 patients with both axillas and other findings had a true positive result and three of 26 had a false positive result. Overall, 45 out of 78 patients were true positive and 33 were false positive. Conclusion Axillary findings are relatively frequent and can be isolated or in association with other findings. In patients with axillary involvement only the frequency of false positivity results is elevated and therefore these cases need to be evaluated carefully. In contrast, axillary findings associated with other pathological localizations show true positive results in most cases, thus indicating a high likelihood of disease recurrence. Standardized uptake values showed a limited role for discriminating true-positive and false-positive findings. Nucl Med Commun 29:705-710

Original languageEnglish
Pages (from-to)705-710
Number of pages6
JournalNuclear Medicine Communications
Volume29
Issue number8
DOIs
Publication statusPublished - Aug 2008

Fingerprint

Fluorodeoxyglucose F18
Lymphoma
Axilla
Hodgkin Disease
Positron-Emission Tomography
Non-Hodgkin's Lymphoma
Recurrence
Ultrasonography
Tomography

Keywords

  • Clinical significance during follow-up
  • Fluorodeoxyglucose-PET axillary finding
  • Lymphoma patients

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Clinical significance of axillary findings in patients with lymphoma during follow-up with 18F-fluorodeoxyglucose-PET. / Tsamita, Charoula S.; Golemi, Arber; Egesta, Lapci; Castellucci, Paolo; Nanni, Cristina; Stefoni, Vittorio; Grassetto, Gaia; Rubello, Domenico; Tani, Monica; Zinzani, Pier Luigi; Fanti, Stefano.

In: Nuclear Medicine Communications, Vol. 29, No. 8, 08.2008, p. 705-710.

Research output: Contribution to journalArticle

Tsamita, CS, Golemi, A, Egesta, L, Castellucci, P, Nanni, C, Stefoni, V, Grassetto, G, Rubello, D, Tani, M, Zinzani, PL & Fanti, S 2008, 'Clinical significance of axillary findings in patients with lymphoma during follow-up with 18F-fluorodeoxyglucose-PET', Nuclear Medicine Communications, vol. 29, no. 8, pp. 705-710. https://doi.org/10.1097/MNM.0b013e328301836d
Tsamita, Charoula S. ; Golemi, Arber ; Egesta, Lapci ; Castellucci, Paolo ; Nanni, Cristina ; Stefoni, Vittorio ; Grassetto, Gaia ; Rubello, Domenico ; Tani, Monica ; Zinzani, Pier Luigi ; Fanti, Stefano. / Clinical significance of axillary findings in patients with lymphoma during follow-up with 18F-fluorodeoxyglucose-PET. In: Nuclear Medicine Communications. 2008 ; Vol. 29, No. 8. pp. 705-710.
@article{bdb20b59ce3f4a0c8bcb4a9763c5fedf,
title = "Clinical significance of axillary findings in patients with lymphoma during follow-up with 18F-fluorodeoxyglucose-PET",
abstract = "Purpose The aim of this study was to evaluate the clinical significance of positive axillary findings in patients with Hodgkin's disease and non-Hodgkin's lymphoma during follow-up with 18F-fluorodeoxyglucose-PET. Materials and methods We retrospectively reviewed PET scans carried out in 543 patients during follow-up. Patients with reports describing any increased fluorodeoxyglucose uptake at the axillary level were selected (106 cases) and final assessment of the findings was available in 78 patients (17 Hodgkin's disease, 51 non-Hodgkin's lymphoma). PET scans were performed after standard procedure and reports were interpreted as positive or negative on the basis of visual analysis. At the moment of the scan all patients had no clinical or laboratory sign of relapse, and had not received therapy for at least 6 months. All PET results were compared with other diagnostic procedures (ultrasonography and computed tomography), biopsy and/or follow-up data. Results Of 78 patients, 24 were PET positive in one axilla, 23 had axillary findings and one or more other extra axillary sites, five patients were positive in both axillas and 26 were positive in both axillas and one or more other sites. Of the 24 patients with single axillary finding, the result for five was true positive and for 19 it was false positive. Sixteen cases of the 23 patients with PET positive at one axilla and other sites had a true positive result, whereas seven had a false positive result. Only one of five patients with both axillas being positive at PET turned out to be true positive; finally, 23 cases from the 26 patients with both axillas and other findings had a true positive result and three of 26 had a false positive result. Overall, 45 out of 78 patients were true positive and 33 were false positive. Conclusion Axillary findings are relatively frequent and can be isolated or in association with other findings. In patients with axillary involvement only the frequency of false positivity results is elevated and therefore these cases need to be evaluated carefully. In contrast, axillary findings associated with other pathological localizations show true positive results in most cases, thus indicating a high likelihood of disease recurrence. Standardized uptake values showed a limited role for discriminating true-positive and false-positive findings. Nucl Med Commun 29:705-710",
keywords = "Clinical significance during follow-up, Fluorodeoxyglucose-PET axillary finding, Lymphoma patients",
author = "Tsamita, {Charoula S.} and Arber Golemi and Lapci Egesta and Paolo Castellucci and Cristina Nanni and Vittorio Stefoni and Gaia Grassetto and Domenico Rubello and Monica Tani and Zinzani, {Pier Luigi} and Stefano Fanti",
year = "2008",
month = "8",
doi = "10.1097/MNM.0b013e328301836d",
language = "English",
volume = "29",
pages = "705--710",
journal = "Nuclear Medicine Communications",
issn = "0143-3636",
publisher = "Lippincott Williams and Wilkins",
number = "8",

}

TY - JOUR

T1 - Clinical significance of axillary findings in patients with lymphoma during follow-up with 18F-fluorodeoxyglucose-PET

AU - Tsamita, Charoula S.

AU - Golemi, Arber

AU - Egesta, Lapci

AU - Castellucci, Paolo

AU - Nanni, Cristina

AU - Stefoni, Vittorio

AU - Grassetto, Gaia

AU - Rubello, Domenico

AU - Tani, Monica

AU - Zinzani, Pier Luigi

AU - Fanti, Stefano

PY - 2008/8

Y1 - 2008/8

N2 - Purpose The aim of this study was to evaluate the clinical significance of positive axillary findings in patients with Hodgkin's disease and non-Hodgkin's lymphoma during follow-up with 18F-fluorodeoxyglucose-PET. Materials and methods We retrospectively reviewed PET scans carried out in 543 patients during follow-up. Patients with reports describing any increased fluorodeoxyglucose uptake at the axillary level were selected (106 cases) and final assessment of the findings was available in 78 patients (17 Hodgkin's disease, 51 non-Hodgkin's lymphoma). PET scans were performed after standard procedure and reports were interpreted as positive or negative on the basis of visual analysis. At the moment of the scan all patients had no clinical or laboratory sign of relapse, and had not received therapy for at least 6 months. All PET results were compared with other diagnostic procedures (ultrasonography and computed tomography), biopsy and/or follow-up data. Results Of 78 patients, 24 were PET positive in one axilla, 23 had axillary findings and one or more other extra axillary sites, five patients were positive in both axillas and 26 were positive in both axillas and one or more other sites. Of the 24 patients with single axillary finding, the result for five was true positive and for 19 it was false positive. Sixteen cases of the 23 patients with PET positive at one axilla and other sites had a true positive result, whereas seven had a false positive result. Only one of five patients with both axillas being positive at PET turned out to be true positive; finally, 23 cases from the 26 patients with both axillas and other findings had a true positive result and three of 26 had a false positive result. Overall, 45 out of 78 patients were true positive and 33 were false positive. Conclusion Axillary findings are relatively frequent and can be isolated or in association with other findings. In patients with axillary involvement only the frequency of false positivity results is elevated and therefore these cases need to be evaluated carefully. In contrast, axillary findings associated with other pathological localizations show true positive results in most cases, thus indicating a high likelihood of disease recurrence. Standardized uptake values showed a limited role for discriminating true-positive and false-positive findings. Nucl Med Commun 29:705-710

AB - Purpose The aim of this study was to evaluate the clinical significance of positive axillary findings in patients with Hodgkin's disease and non-Hodgkin's lymphoma during follow-up with 18F-fluorodeoxyglucose-PET. Materials and methods We retrospectively reviewed PET scans carried out in 543 patients during follow-up. Patients with reports describing any increased fluorodeoxyglucose uptake at the axillary level were selected (106 cases) and final assessment of the findings was available in 78 patients (17 Hodgkin's disease, 51 non-Hodgkin's lymphoma). PET scans were performed after standard procedure and reports were interpreted as positive or negative on the basis of visual analysis. At the moment of the scan all patients had no clinical or laboratory sign of relapse, and had not received therapy for at least 6 months. All PET results were compared with other diagnostic procedures (ultrasonography and computed tomography), biopsy and/or follow-up data. Results Of 78 patients, 24 were PET positive in one axilla, 23 had axillary findings and one or more other extra axillary sites, five patients were positive in both axillas and 26 were positive in both axillas and one or more other sites. Of the 24 patients with single axillary finding, the result for five was true positive and for 19 it was false positive. Sixteen cases of the 23 patients with PET positive at one axilla and other sites had a true positive result, whereas seven had a false positive result. Only one of five patients with both axillas being positive at PET turned out to be true positive; finally, 23 cases from the 26 patients with both axillas and other findings had a true positive result and three of 26 had a false positive result. Overall, 45 out of 78 patients were true positive and 33 were false positive. Conclusion Axillary findings are relatively frequent and can be isolated or in association with other findings. In patients with axillary involvement only the frequency of false positivity results is elevated and therefore these cases need to be evaluated carefully. In contrast, axillary findings associated with other pathological localizations show true positive results in most cases, thus indicating a high likelihood of disease recurrence. Standardized uptake values showed a limited role for discriminating true-positive and false-positive findings. Nucl Med Commun 29:705-710

KW - Clinical significance during follow-up

KW - Fluorodeoxyglucose-PET axillary finding

KW - Lymphoma patients

UR - http://www.scopus.com/inward/record.url?scp=55249124992&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=55249124992&partnerID=8YFLogxK

U2 - 10.1097/MNM.0b013e328301836d

DO - 10.1097/MNM.0b013e328301836d

M3 - Article

C2 - 18753823

AN - SCOPUS:55249124992

VL - 29

SP - 705

EP - 710

JO - Nuclear Medicine Communications

JF - Nuclear Medicine Communications

SN - 0143-3636

IS - 8

ER -